Showing 1451-1460 of 2150 results for "".
- VisionHQ Establishes Advisory Boardhttps://modernod.com/news/visionhq-establishes-advisory-board/2486441/VisionHQ, which provides in-house membership management and loyalty platform for eye care providers, has announced the formation of its Advisory Board. The move marks a strategic step forward in the company’s mission to help optometry practices boost patient retenti
- Nordic Pharma Announces European Launch of Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-announces-european-launch-of-lacrifill-canalicular-gel/2485691/Nordic Group, the parent company of Nordic Pharma, announced the European launch of Lacrifill, a novel therapy for the management of dry eye disease. Following CE mark approval in April 2025, Lacrifill is now available to healthcare professionals and patients acros
- NICE Approves First NHS Treatment for Leber Hereditary Optic Neuropathy (LHON)https://modernod.com/news/nice-approves-first-nhs-treatment-for-leber-hereditary-optic-neuropathy-lhon/2484140/The UK-based National Institute for Health and Care Excellence (NICE) has approved idebenone (Raxone; Chiesi Pharmaceuticals) for the treatment of Leber Hereditary Optic Neuropathy (LHON) in patients aged 12 years and older. This marks the first time NICE has
- Bascom Palmer Eye Institute Tops U.S. News & World Report Rankings for 24th Year in a Rowhttps://modernod.com/news/bascom-palmer-eye-institute-tops-us-news-world-report-rankings-for-24th-year-in-a-row/2482911/For the 24th year, Bascom Palmer Eye Institute has been ranked the No. 1 ophthalmology hospital in the United States, according to the newly released 2025 U.S. News & World Report "Best Hospitals" rankings. This marks the 22nd consecutive year th
- Nanoscope Initiates Rolling Submission of BLA to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat RPhttps://modernod.com/news/nanoscope-initiates-rolling-submission-of-bla-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-rp/2482884/Nanoscope Therapeutics announced the initiation of a rolling submission of a biologics license application (BLA) to the FDA for its lead investigational therapy, MCO-010, for the treatment of severe vision loss due to retinitis pigmentosa (RP). This marks a significant re
- Allotex Files IDE with FDA for Collagen-Based Corneal Implanthttps://modernod.com/news/allotex-files-ide-with-fda-for-collagen-based-corneal-implant/2482813/Allotex announced the submission of its investigational device exemption (IDE) to the FDA, marking a step toward US clinical trials of the company’s human collagen-based corneal implant, Allo-1. Allo-1 offers a novel approach to near vision enhancement through biolo
- Zeiss to Showcase New Digital Technologies at ASCRShttps://modernod.com/news/zeiss-to-showcase-new-digital-technologies-at-ascrs/2482742/Zeiss Medical Technology will celebrate the adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25–27 in Los Angeles. Zeiss marks a ma
- China’s First IGF-1R Monoclonal Antibody Approved, Innovent Biologics Announceshttps://modernod.com/news/chinas-first-igf-1r-monoclonal-antibody-approved-innovent-biologics-announces/2482701/Innovent Biologics announced China’s approval of SYCUME® for thyroid eye disease (TED) earlier this week. SYCUME® is China’s first monoclonal antibody therapeutic option for TED and only the second available globally – marking the first new treatment
- Kala Bio Announces Chief Executive Officer Transitionhttps://modernod.com/news/kala-bio-announces-chief-executive-officer-transition/2482662/Kala Bio announced the resignation of Chief Executive Officer Mark Iwicki, and the appointment of Todd Bazemore, Kala's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of Kala fol
- Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinkinghttps://modernod.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. “Op